Advertisement
Screener

ACLARION, INC. (ACON) Adjustments to Additional Paid in Capital, Other

2.8 / 5 stars · 68/120 Roast Me

ACLARION, INC. Adjustments to Additional Paid in Capital, Other

ACLARION, INC. (ACON) reported Adjustments to Additional Paid in Capital, Other of $698.06 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital

us-gaap:AdjustmentsToAdditionalPaidInCapitalOther · last filed 2026-08-06

  • ACLARION, INC. adjustments to additional paid in capital, other for the quarter ending 2026-06-30 was $6.33K, a 65.15% decline year-over-year.
  • ACLARION, INC. adjustments to additional paid in capital, other for the quarter ending 2026-03-31 was $691.74K, a 67.06% decline year-over-year.
  • ACLARION, INC. adjustments to additional paid in capital, other for the quarter ending 2025-12-31 was $281.85K.
  • ACLARION, INC. adjustments to additional paid in capital, other for the quarter ending 2025-09-30 was $0.00.
  • ACLARION, INC. adjustments to additional paid in capital, other for fiscal 2025 was $2.40M, a 118.18% increase from fiscal 2024.
  • ACLARION, INC. adjustments to additional paid in capital, other for fiscal 2024 was $1.10M.
  • ACLARION, INC. adjustments to additional paid in capital, other for fiscal 2022 was -$530.46K.
Period endAdjustments to Additional Paid in Capital, Other 3 monthAdjustments to Additional Paid in Capital, Other 6 monthAdjustments to Additional Paid in Capital, Other 9 monthAdjustments to Additional Paid in Capital, Other 12 month
2026-06-30$6.33K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
$698.06K
10-Q · filed 2026-08-06
$979.91K
derived: sum of 3 quarters · filed 2026-08-06
$979.91K
derived: sum of 4 quarters · filed 2026-08-06
2026-03-31$691.74K
10-Q · filed 2026-05-13
$973.59K
derived: sum of 2 quarters · filed 2026-05-13
$973.59K
derived: sum of 3 quarters · filed 2026-05-13
$991.74K
derived: sum of 4 quarters · filed 2026-05-13
2025-12-31$281.85K
derived: 10-K 12 month − 3 quarters · filed 2026-03-18
$281.85K
derived: sum of 2 quarters · filed 2026-03-18
$300.00K
derived: sum of 3 quarters · filed 2026-03-18
$2.40M
10-K · filed 2026-03-18
2025-09-30$0.00
10-Q · filed 2025-11-12
$18.15K
derived: sum of 2 quarters · filed 2025-11-12
$2.12M
derived: sum of 3 quarters · filed 2025-11-12
2025-06-30$18.15K
10-Q · filed 2025-08-14
$2.12M
derived: sum of 2 quarters · filed 2025-11-12
2025-03-31$2.10M
10-Q · filed 2025-11-12
2024-12-31$1.10M
10-K · filed 2026-03-18
2023-06-30$37.50K
10-Q · filed 2023-08-25
2022-12-31-$530.46K
10-K · filed 2024-03-28
2022-06-30-$530.46K
10-Q · filed 2023-11-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
Advanced Biomed Inc. (ADVB)$0.009B
AMERICAN SHARED HOSPITAL SERVICES (AMS)United States$0.010B-5.64
BioNexus Gene Lab Corp (BGLC)$0.004B
SERA PROGNOSTICS, INC. (SERA)United States$0.062B-5.75
Freenome, Inc. (FRNM)United States$0.143B
EXAGEN INC. (XGN)United States$0.212B-5.95
BIODESIX INC (BDSX)United States$0.312B
Fulgent Genetics, Inc. (FLGT)United States$0.593B-6.70
Lumexa Imaging Holdings, Inc. (LMRI)United States$0.951B
CASTLE BIOSCIENCES INC (CSTL)United States$1.074B-37.45